Clinical trials: Digestive System Cancer
Barrett's Esophagus, Esophageal Cancer
University of North Carolina (UNC) Barrett's Esophagus and Esophageal Cancer Biorepository
Aim 1: To develop a prospective tissue and blood biorepository from patients with a history of Barrett's Esophagus (BE) or esophageal cancer (ECA) presenting to UNC hospitals for routine care upper endoscopy for their condition.
- Conditions
- Barrett's Esophagus, Esophageal Cancer, Intramucosal Adenocarcinoma
- Trial name
- BEECAB (NCT02427269)
- Testing
- Specimen Collection
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of North Carolina, Chapel Hill
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Solid Tumor, Gastric Cancer
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT04400383
- Testing
- AB011 Injection
- Where
- 12 sites in China
- Volunteers
- 62 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Anal Cancer
Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic Radiotherapy
A commercially available vaginal dilator set will be used as measuring device. The grading of vaginal stenosis will be determined as difference of the diameter of vaginal dilator to the baseline.
- Trial name
- DILANA (NCT04094454)
- Testing
- special tampon with a diameter of 28mm, standard tampon with a diameter of 12-13mm
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Juergen Debus
Stomach Neoplasm, Gastrointestinal Neoplasms
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
Our main objective is to evaluate the effect of Ocoxin-Viusid on the quality of life of patients with advanced stomach cancer and esophagogastric junction.
- Conditions
- Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Esophageal Neoplasms
- Trial name
- NCT03549494
- Testing
- Ocoxin-Viusid®
- Where
- Cuba
- Volunteers
- 45 people
- Sponsor
- Catalysis SL
Rectal Cancer
Influence of Lengthening the Interval Between Radiochemotherapy and Surgery on Complete Pathological Response in Rectal Cancer
At the end of the neoadjuvant radiochemotherapy, patients are seen by their surgeon to planify the surgery. During this visit, the study will be explained them and their consent obtained.
- Trial name
- GRECCAR6 (NCT01648894)
- Testing
- Surgery after 11 weeks of delay after chemoradiotherapy., Surgery after 7 weeks of delay after chemoradiotherapy
- Where
- France
- Volunteers
- 265 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced or Metastatic Solid Tumor, Liver Failure
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
- Trial name
- NCT04617522
- Testing
- Sacituzumab Govitecan-hziy
- Where
- 15 sites in United States, France and 2 more
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Gastric Cancer
Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients
Open-label, multicenter study to assess 250µg/0.2ml G17DT injection at weeks 0, 2 and 6. At or after week 20 and up to and including week 44.
- Trial name
- NCT02518529
- Testing
- G17DT
- Volunteers
- 41 people
- Sponsor
- Cancer Advances Inc.
Cervical Cancer, Endometrial Cancer
Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study
The primary aim of the trial is to investigate the late effects of hypofractionated external radiation (39 Gy in 13 fractions) in patients requiring post-operative radiation for early-stage cervical and endometrial cancers.
- Trial name
- PARCERII (NCT05857631)
- Testing
- Hypofractionated Image guided External Beam Radiation Therapy (EBRT), Cisplatin, Vaginal brachytherapy
- Where
- 2 sites in India
- Volunteers
- 90 people
- Sponsor
- Tata Memorial Centre
Anastomotic Leakage in Colon Surgery, Anastomotic Leak Rectum
Anastomotic Leakage in Colorectal Cancer Surgery in Syria
Anastomotic leakage is a serious complication of colorectal cancer surgery, particularly in resource-limited and conflict-affected settings.
- Conditions
- Anastomotic Leakage in Colon Surgery, Anastomotic Leak Rectum, Anastomotic Leak Large Intestine
- Trial name
- NCT07092631
- Where
- Syria
- Volunteers
- 119 people
- Sponsor
- Elie Bitar
Hepatocellular Carcinoma
Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a common cause of cancer mortality in Asia. Most patients present with intermediate or advanced disease.
- Trial name
- NCT01328223
- Testing
- sorafenib and radiotherapy for hepatocellular carcinoma
- Where
- 3 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- China Medical University Hospital
Hepatocellular Carcinoma
Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC
This study aims to evaluate the safety and efficacy of aprepitant combined with granisetron and dexamethasone versus granisetron and dexamethasone in the prevention of nausea and vomiting in patients with hepatocellular carcinoma…
- Trial name
- NCT05711823
- Testing
- Aprepitant in combination with granisetron and dexamethasone, Granisetron and dexamethasone
- Volunteers
- 300 people
- Sponsor
- Guangxi Medical University
Pancreatic Cancer
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
The aim of this study is to evaluate the safety and effectiveness of Fruquintinib combined with Albumin Paclitaxel and Gemcitabine on pancreatic cancer patients with liver metastases. Plan to enrollment 30 patients.
- Trial name
- NCT05168527
- Testing
- Fruquintinib,Albumin Paclitaxel,Gemcitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Gastric Cancer, Total Gastrectomy
Enhanced vs. Routine Follow-Up After Total Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial
The goal of this clinical trial is to compare the effectiveness of enhanced follow-up with standard follow-up in postoperative patients with advanced gastric cancer who have undergone radical gastrectomy.
- Conditions
- Gastric Cancer, Total Gastrectomy, Postoperative Care, Quality of Life
- Trial name
- NCT06468969
- Testing
- Enhanced Follow-up
- Volunteers
- 158 people
- Sponsor
- Fudan University
Pancreatic Cancer
New Treatment Option for Pancreatic Cancer
In the United States, approximately 30,000 new cases of pancreatic cancer are diagnosed each year and an almost equal number of deaths are related to this cancer.
- Trial name
- NCT01364805
- Testing
- Intravenous Vitamin C, Gemcitabine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jeanne Drisko, MD, CNS, FACN
Esophageal Cancer, Esophageal Carcinoma
Robot-assisted Esophagectomy Versus Conventional Thoracoscopic Esophagectomy
This is the first randomized controlled study to compare the robot-assisted esophagectomy (RAE) to minimally invasive conventional thoracoscopic esophagectomy (CTE).
- Trial name
- RAE vs CTE (NCT03094351)
- Testing
- esophagectomy
- Where
- 6 sites in China
- Volunteers
- 360 people
- Sponsor
- Shanghai Chest Hospital
Carcinoma, Hepatocellular, Lenvatinib
Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial
The purpose of this clinical trial is to evaluate the efficacy and safety of regorafenib as a subsequent therapy for patients with hepatocellular carcinoma (HCC) who have failed prior lenvatinib treatment.
- Conditions
- Carcinoma, Hepatocellular, Lenvatinib, Treatment Failure
- Trial name
- RELEVANT-HCC (NCT07514429)
- Testing
- Regorafenib (BAY 73-4506)
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Ju Hyun Shim
Biliary Tract Cancer
ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial
A substantial proporation of patients with biliary tract malignancies still experience disease recurrence after curative resection.
- Trial name
- NCT05743959
- Testing
- No intervention
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
Phase II - Treatment Regimen Exploration Stage: 1. Evaluate the safety and efficacy of the following three treatment regimens: Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart (Group A) Liposomal irinotecan + 5-FU/LV +…
- Conditions
- Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan, Second-Line
- Trial name
- NCT07585279
- Testing
- Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart, Irinotecan liposome + 5-FU/LV + Bevacizumab, Irinotecan + 5-FU/LV + Bevacizumab
- Where
- China
- Volunteers
- 408 people
- Sponsor
- Hebei Medical University Fourth Hospital
Solid Tumor
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Some types of cancer are caused by changes, or mutations, in a gene called KRAS.
- Trial name
- NCT06364696
- Testing
- ASP4396
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.